Sangamo Biosciences (SGMO) : Fic Capital Inc reduced its stake in Sangamo Biosciences by 0.88% during the most recent quarter end. The investment management company now holds a total of 862,544 shares of Sangamo Biosciences which is valued at $5.3 Million after selling 7,670 shares in Sangamo Biosciences , the firm said in a disclosure report filed with the SEC on May 12, 2016.Sangamo Biosciences makes up approximately 2.62% of Fic Capital Inc’s portfolio.
Other Hedge Funds, Including , First City Capital Management reduced its stake in SGMO by selling 900 shares or 90.0% in the most recent quarter. The Hedge Fund company now holds 100 shares of SGMO which is valued at $610. Nine Chapters Capital Management sold out all of its stake in SGMO during the most recent quarter. The investment firm sold 50,200 shares of SGMO which is valued $306,220.
Sangamo Biosciences opened for trading at $6.05 and hit $6.27 on the upside on Friday, eventually ending the session at $6.27, with a gain of 4.33% or 0.26 points. The heightened volatility saw the trading volume jump to 6,15,003 shares. Company has a market cap of $442 M.
On the company’s financial health, Sangamo Biosciences reported $-0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 2, 2016. Analyst had a consensus of $-0.25. The company had revenue of $3.94 million for the quarter, compared to analysts expectations of $5.49 million. The company’s revenue was down -70.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Company’s lead ZFP Therapeutic SB-728-T a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Company’s clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.